Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence.
OBJECTIVES Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...